Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Sodium and chloride dependent glycine transporter 1 is a protein encoded by the SLC6A9 gene. The Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) pipeline drugs market research report provides comprehensive information on the Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics development with respective active and dormant or discontinued projects.

Glyt1 Pipeline Drugs Market Segmentation by Therapy Areas

The key therapy areas of the Glyt1 pipeline drugs market are central nervous system, genetic disorders, hematological disorders, and metabolic disorders. Central nervous system dominates the pipeline market.

Glyt1 Pipeline Drugs Market Analysis, by Therapy Areas

Glyt1 Pipeline Drugs Market Analysis, by Therapy AreasFor more Glyt1 pipeline drugs market therapy areas insights, download a free report sample

Glyt1 Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanism of action of the Glyt1 pipeline drugs market is Sodium and Chloride Dependent Glycine Transporter 1 Inhibitor.

Glyt1 Pipeline Drugs Market Segmentation by Routes of Administration

The key route of administration in the Glyt1 pipeline drugs market is oral.

Glyt1 Pipeline Drugs Market Segmentation by Molecule Types

The key molecule type in the Glyt1 pipeline drugs market is small molecule.

Glyt1 Pipeline Drugs Market - Competitive Landscape

The leading companies in the Glyt1 pipeline drugs market are AbbVie Inc, Boehringer Ingelheim International GmbH, ConSynance Therapeutics Inc, Dart NeuroScience LLC, Disc Medicine Inc, Mental-Heal Ltd, and Pfizer Inc. Disc Medicine Inc dominates the market in 2022.

Glyt1 Pipeline Drugs Market Analysis, by Companies

Glyt1 Pipeline Drugs Market Analysis, by CompaniesTo know more about the companies in the Glyt1 pipeline drugs market, download a free report sample

Glyt1 Pipeline Drugs Market Report Overview

Key Therapy Areas Central Nervous System, Genetic Disorders, Hematological Disorders, and Metabolic Disorders
Key Mechanism of Action Sodium And Chloride Dependent Glycine Transporter 1 Inhibitor
Key Route of Administration Oral
Key Molecule Type Small Molecule
Leading Companies AbbVie Inc, Boehringer Ingelheim International GmbH, ConSynance Therapeutics Inc, Dart NeuroScience LLC, Disc Medicine Inc, Mental-Heal Ltd, and Pfizer Inc

Scope

  • The report provides a snapshot of the global therapeutic landscape for Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9).
  • The report reviews Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing, and collaboration details & other developmental activities.
  • The report reviews key players involved in Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics and enlists all their major and minor projects.
  • The report assesses Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
  • The report summarizes all the dormant and discontinued pipeline projects.
  • The report reviews the latest news and deals related to Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics.

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9). Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

AbbVie Inc
Boehringer Ingelheim International GmbH
ConSynance Therapeutics Inc
Dart NeuroScience LLC
Disc Medicine Inc
Mental-Heal Ltd
Pfizer Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) – Overview

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) – Companies Involved in Therapeutics Development

AbbVie Inc

Boehringer Ingelheim International GmbH

ConSynance Therapeutics Inc

Dart NeuroScience LLC

Disc Medicine Inc

Mental-Heal Ltd

Pfizer Inc

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) – Drug Profiles

bitopertin – Drug Profile

Product Description

Mechanism Of Action

History of Events

CSTI-200 – Drug Profile

Product Description

Mechanism Of Action

DNS-006 – Drug Profile

Product Description

Mechanism Of Action

iclepertin – Drug Profile

Product Description

Mechanism Of Action

History of Events

PF-03463275 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PGW-5 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit GlyT1 for Parkinson’s Disease and Schizophrenia – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit Glyt1 for Schizophrenia – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit Glyt1 for Unspecified Hematological Disorders – Drug Profile

Product Description

Mechanism Of Action

History of Events

VU-0410120 – Drug Profile

Product Description

Mechanism Of Action

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) – Dormant Products

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) – Discontinued Products

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) – Product Development Milestones

Featured News & Press Releases

Nov 03, 2022: Disc Medicine announces presentations on Bitopertin across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting

Oct 31, 2022: Disc Medicine initiates AURORA, a phase 2 clinical study of Bitopertin in adults with Erythropoietic Protoporphyria (EPP)

Aug 10, 2022: Disc Medicine initiates BEACON, a phase 2 clinical study of Bitopertin in patients with Erythropoietic Protoporphyria (EPP) and X-linked Protoporphyria (XLP)

Nov 11, 2021: Disc Medicine announces oral presentation on bitopertin at the 63rd American Society of Hematology Annual Meeting

May 24, 2021: Boehringer Ingelheim’s investigational treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation

Sep 15, 2020: Boehringer’s drug improves cognition in Phase II schizophrenia trial

Jan 21, 2014: Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia

Dec 06, 2010: Phase II Study With First-In-Class Investigational Drug Demonstrates Improvement In Negative Symptoms In Patients With Schizophrenia

Dec 06, 2010: Roche Announces Eight-Week Results From Phase II Study Of RG16781 In Patients With Schizophrenia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AbbVie Inc, 2022

Pipeline by Boehringer Ingelheim International GmbH, 2022

Pipeline by ConSynance Therapeutics Inc, 2022

Pipeline by Dart NeuroScience LLC, 2022

Pipeline by Disc Medicine Inc, 2022

Pipeline by Mental-Heal Ltd, 2022

Pipeline by Pfizer Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Frequently asked questions

Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.